Detecting improvements in dyspnea in COPD using a three-minute constant rate shuttle walking protocol

COPD. 2012 Aug;9(4):395-400. doi: 10.3109/15412555.2012.674164. Epub 2012 Apr 18.

Abstract

Rationale: We examined the responsiveness of a 3-minute constant rate shuttle walking protocol to detect improvements in exertional dyspnea following acute bronchodilation in COPD. Our hypothesis was that the 3-minute constant rate shuttle walking protocol would be able to adequately put forth improvements in exertional dyspnea following acute bronchodilation in this population.

Methods: Using a placebo controlled, double-blind cross-over design, 39 patients with moderate to severe COPD performed a 3-min constant rate shuttle walking test during which they were asked to walk on a flat corridor at a speed that was externally imposed by an audio signal. During the test, dyspnea was graded using the 10-point modified Borg scale. The test was performed twice, following the administration of saline placebo or of 500 μg nebulized ipratropium bromide.

Results: Improvements of respiratory pattern (respiratory rate and tidal volume) and statistically and clinically significant reductions in Borg dyspnea scores (∆ dyspnea score = 1.0 ± 0.2, p < 0.01) were seen during the 3-min shuttle walking protocol with ipratropium bromide compared to placebo.

Conclusion: This 3-minute shuttle walking protocol adequately detected dyspnea and breathing pattern improvements following acute bronchodilation in COPD.

Trial registration: ClinicalTrials.gov NCT00807534.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bronchodilator Agents / therapeutic use*
  • Double-Blind Method
  • Dyspnea / diagnosis*
  • Dyspnea / drug therapy
  • Dyspnea / etiology
  • Exercise Test / methods*
  • Female
  • Humans
  • Ipratropium / therapeutic use*
  • Male
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Respiratory Function Tests
  • Treatment Outcome
  • Walking*

Substances

  • Bronchodilator Agents
  • Ipratropium

Associated data

  • ClinicalTrials.gov/NCT00807534